[Clinical administration of hematopoietic growth factors. When and where?].
Ottmann
O G
OG
Medizinische Klinik III Hämatologie, Onkologie, Rheumatologie, Infektionskrankheiten der Johann-Wolfgang-Goethe Universität, Frankfurt/Main.
Seipelt
G
G
Hoelzer
D
D
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D016298:Hematopoietic Cell Growth Factors / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D009503:Neutropenia / Q000139:chemically induced / Q000628:therapy*; D009894:Opportunistic Infections / Q000276:immunology / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic
D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor
Klinischer Einsatz hämatopoetischer Wachstumsfaktoren. Wann und Wo?